MedTrace Logo

Biomarkers of Efficacy and Tolerability of Sacituzumab-Govitecan in the Treatment of Patients With Triple-negative Breast Cancer in the Metastatic Phase: Prospective Multicenter Real-world Study

NCT06240195 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-03-25

No results posted yet for this study

Summary

Observational, prospective, multicenter study. Collection of data relating to the effectiveness of sacituzumab govitecan SG, in a real-world context and planned research of predictive biomarkers of efficacy/tolerability carried out on multiple platforms at the center coordinator.

Conditions

Interventions

OTHER

data collection

Collection of data relating to the effectiveness of sacituzumab govitecan and evaluation in a real-world context and planned research of predictive biomarkers of efficacy/tolerability

Sponsors & Collaborators

  • Ospedale Sandro Pertini, Roma

    collaborator OTHER

  • Catholic University of the Sacred Heart

    collaborator OTHER

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    collaborator OTHER

  • Campus Bio-Medico University

    collaborator OTHER

  • Azienda Policlinico Umberto I

    collaborator OTHER

  • San Giovanni Addolorata Hospital

    collaborator OTHER

  • Ospedale "SS Annunziata", Chieti

    collaborator UNKNOWN

  • Ospedale "Gaetano Bernabeo" , Ortona

    collaborator UNKNOWN

  • Hospital San Pietro Fatebenefratelli

    collaborator OTHER

  • presidio Ospedaliero santo spirito in Sassia, Roma

    collaborator UNKNOWN

  • Ospedale di Belcolle - Viterbo

    collaborator UNKNOWN

  • Regina Elena Cancer Institute

    lead OTHER

Principal Investigators

  • Patrizia Vici, Doctor · IRCCS "Regina Elena" National Cancer Institute

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-17
Primary Completion
2025-01-17
Completion
2025-06-17

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06240195 on ClinicalTrials.gov